Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Yoon, Eileen L. | - |
dc.contributor.author | Kim, Chang Wook | - |
dc.contributor.author | Lee, Chang Don | - |
dc.contributor.author | Park, Sang Hoon | - |
dc.contributor.author | Lee, Myung Seok | - |
dc.contributor.author | Park, Choong Kee | - |
dc.contributor.author | Chae, Hee Bok | - |
dc.contributor.author | Kim, Moon Young | - |
dc.contributor.author | Baik, Soon Koo | - |
dc.contributor.author | Kim, Yun Soo | - |
dc.contributor.author | Kim, Ju Hyun | - |
dc.contributor.author | Il Lee, Jung | - |
dc.contributor.author | Lee, Jin Woo | - |
dc.contributor.author | Hong, Sun Pyo | - |
dc.contributor.author | Um, Soon Ho | - |
dc.date.accessioned | 2021-09-06T04:44:02Z | - |
dc.date.available | 2021-09-06T04:44:02Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-02 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/104065 | - |
dc.description.abstract | Background Management of lamivudine-resistant chronic hepatitis B (CHB) remains challenging, as inappropriate choice of treatment may cause multidrug resistance. Until now, randomized trials directly comparing adding adefovir and switching to entecavir monotherapy have not been reported. Aims This multicentre prospective randomized study was designed to compare the efficacy of these two strategies. Methods Two hundred and nineteen lamivudine-resistant CHB patients were randomized to either adefovirlamivudine combination group or entecavir monotherapy group (n = 110 vs. 109), and followed up for 24 months. Results One hundred and eighty patients completed this study. At month 24, virological response rate [hepatitis B virus (HBV) DNA <60 IU/ml] was higher in the adefovirlamivudine combination group compared with entecavir group (56.7% vs. 40%, P = 0.025), although biochemical and serological response rates were not significantly different. Genotypic resistance (9.2% vs. 24.6%, P = 0.005) and combined viral breakthrough (2.0% vs. 17.6%, P < 0.001) were more frequent in the entecavir group. However, by subgroup analysis, virological response rates were not significantly different between the two therapies in HBeAg-positive patients (44.9% vs. 35.7%, P = 0.268) or in patients with high baseline HBV DNA (=7 log IU/ml) (40.7% vs. 31.3%, P = 0.320) at month 24. Conclusion This study showed that adefovirlamivudine combination provides significantly higher antiviral efficacy and the lower resistance rate compared with the entecavir monotherapy in the management of lamivudine-resistant CHB. However, it had limited efficacy in HBeAg-positive patients or in patients with high baseline HBV DNA. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | VIRUS INFECTION | - |
dc.subject | THERAPY | - |
dc.subject | MONOTHERAPY | - |
dc.subject | DNA | - |
dc.subject | BREAKTHROUGH | - |
dc.subject | MANAGEMENT | - |
dc.subject | DIPIVOXIL | - |
dc.subject | DISEASE | - |
dc.subject | UPDATE | - |
dc.title | Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.contributor.affiliatedAuthor | Um, Soon Ho | - |
dc.identifier.doi | 10.1111/liv.12036 | - |
dc.identifier.scopusid | 2-s2.0-84872159453 | - |
dc.identifier.wosid | 000313263000012 | - |
dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, v.33, no.2, pp.244 - 254 | - |
dc.relation.isPartOf | LIVER INTERNATIONAL | - |
dc.citation.title | LIVER INTERNATIONAL | - |
dc.citation.volume | 33 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 244 | - |
dc.citation.endPage | 254 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | VIRUS INFECTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordPlus | BREAKTHROUGH | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | DIPIVOXIL | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | UPDATE | - |
dc.subject.keywordAuthor | adefovir | - |
dc.subject.keywordAuthor | chronic hepatitis B | - |
dc.subject.keywordAuthor | entecavir | - |
dc.subject.keywordAuthor | lamivudine | - |
dc.subject.keywordAuthor | resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.